The presentation marks a pivotal update for the Holon-based biotech company, which centers its pipeline on AI-driven target discovery. Dr. Yeku, an expert in gynecologic oncology, is expected to provide insights into the trial's methodology as the company targets a Q1 2027 window for interim median progression-free survival data. COM701 represents a potential first-in-class treatment, currently moving through clinical evaluation to address the immunosuppressive microenvironment of gynecologic cancers.

Beyond the clinical update, Compugen’s research team will demonstrate enhancements to Unigen™, their proprietary computational platform. This technology serves as the backbone for the company's broader immuno-oncology pipeline, which currently includes collaborations with AstraZeneca and Gilead. Following the technical review of the MAIA-ovarian study and platform advancements, management will host a live question-and-answer session.